N9741:

A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum

ClinicalTrials.gov Identifier: NCT00003594

Study Background

Trial Design:

This is a randomized, multicenter study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior adjuvant chemotherapy (yes vs no), prior immunotherapy (yes vs no), and age (under 65 vs 65 and over). Patients are randomized to one of three treatment arms.

- Arm I (Saltz regimen): Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks. (Arm I closed to accrual as of March 15, 2002.)
- Arm II (FOLFOX4 regimen): Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.
- Arm III (oxaliplatin plus irinotecan): Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks. (Arm III closed to accrual as of March 15, 2002.) Treatment continues in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.

Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

Objectives:

Primary:

- The primary objective of this trial is to compare the time to progression in patients with locally advanced or metastatic colorectal cancer (previously untreated for advanced disease) who receive OXAL + 5-FU + CF or CPT-11 + OXAL (the two experimental regimens) to those receiving CPT-11 + 5-FU + CF (the control regimen).

Secondary:

- A secondary objective of this trial is to compare the time to progression of patients receiving the two experimental regimens.
- The primary secondary outcome measure in this trial is overall survival.
- Other secondary objectives include evaluation of toxicity, response rate, and time to treatment failure.
- To compare quality-of-life parameters in patients on these regimens.

Stratification Factors:

- ECOG PS: 0, 1 vs. 2.
- Prior adjuvant chemotherapy: Yes vs. no.
- Prior immunotherapy: Yes vs. no.
- Age <65 vs. ≥65.
- Membership: Intergroup vs. Expanded Participation Project (EPP).

Study History:

10/27/1998	Activation Date
7/19/2002	Close Date
October 2004	Primary Completion Date
October 2004	Study Completion Date

Publication Information

Analysis Type: Primary Endpoint Analysis

PubMed ID: 14665611

Citation: Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., . . . Alberts, S. R. (2004). A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 22(1), 23-30. doi:10.1200/jco.2004.09.046

Associated Datasets:

NCT00003594_D1crse
NCT00003594_D2cycle
NCT00003594_D3cytox
NCT00003594_D4end_at

Note: These datasets have been updated since the primary publication and may not match the exact results reported in the primary manuscript.

Dataset Information

Dataset Name: NCT00003594_D1crse

Description: The NCT00003594_D1crse dataset is one of 4 datasets associated with PubMed ID 14665611. This dataset contains information regarding patient-level information including eligibility, baseline characteristics, and best response. It also includes information to analyze overall survival and time to progression.

NCT00003594_D1crse Data Dictionary

Variable Description	Variable Name	Code	Notes
Unique identifier for each patient	patref		
Experimental Arm: A, F, G	arm	A = CPT-11, 5-FU, CF F = OXAL G = OXAL + CPT-11	For the purposes of matching the study background and clinicaltrials.gov registration information, Arm I, Arm II, and Arm III are synonymous with Arm A, Arm F and Arm G, respectively.
Disease status	dz_g	1=Measurable 2=Evaluable	
Indicator for reason patients were excluded from analysis	excluded	9=Ineligible 8=Violation 7=Cancel Missing = otherwise	
Follow-up Status	fu_stat	1=alive 2=dead	
Prior adjuvant chemotherapy	pradj_g	1=Yes 2=No	
Prior immunotherapy	prior_im	1=Yes 2=No	
ECOG Performance Status	ps_g	1=0,1 2=2	

Sex	sex	m=Male f=Female	
Grade 4/5 event	bad_tox	1 = patient experienced a grade 4 or 5 adverse event, regardless of attribution 2 = otherwise	If missing patient was not evaluated for adverse events.
Best Response to date	br	1 = Complete Response 2 = Partial Response 3 = Regression 5 = Stable Disease 6 = Progression Missing= Not Assessed	If missing patient did not have a disease assessment.
Grade 5 event	drg_dth	1 = patient experienced a grade 5 adverse event, regardless of attribution 2 = otherwise	See bad_tox.
Evaluable for Toxicity	evalae	1 = at least one Nadir Adverse Event Form is entered other than cycle 0 0 = otherwise	
Evaluable for baseline analysis	evalbl	1 = Evaluable 0 = otherwise	16 pts had missing evalbl. There were 13 cases where pt cancelled prior to treatment (excluded=7). Two cases where pt was deemed ineligible after registering and one case where the pt progressed prior to receiving protocol treatment.
Evaluable For Objective Status analysis	evalresp	1= at least 1 measurement form is entered with at least 1 objective status 0 = otherwise	16 pts had missing evalresp. There were 13 cases where pt cancelled prior to treatment (excluded=7); two cases where pt was deemed ineligible after registering; and one case where the pt progressed prior to receiving protocol treatment.
Determines the maturity of the data on a given patient	evaluabl	1=Registered 2= EVALUABL=1 & On study 3= EVALUABL=2 & Evaluated for at least one toxicity 5= EVALUABL=3 & Evaluated for objective status	
Days from randomization until last contact or death	fu_time	Numeric	

Most recent cycle patient was evaluated for toxicity	last_cy	Numeric	
Progression status	pg_stat	1=Progression Free 2=Progression	
Days from randomization until progression status date	pg_time	Numeric	If pg_stat=1, this is the date the patient was last known to be progression free. If pg_stat=2, this is the date of the patient's first progression.
Age category:	agecat	<35, 35-44, 45-54, 55-64, 65-74, >=75	If missing age was not recorded.
Race category	racecat	b=black w=white oth=other	
Days from randomization until date of best response	br_time	Numeric	If missing best response was not recorded.
Days from randomization until date of first response	fr_time	Numeric	If missing first response was not recorded.